# FDA Approves Perioperative Durvalumab-Padcev for Cisplatin-Ineligible MIBC

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/57025
Published: 2026-11-13T21:33:17.000Z
Updated: 2026-11-13T21:33:17.000Z
Section: Regulation

> The approval covers perioperative use in patients who cannot receive cisplatin-based chemotherapy.

The U.S. Food and Drug Administration approved perioperative use of durvalumab with Padcev (enfortumab vedotin) for patients with muscle-invasive bladder cancer who cannot receive cisplatin-based chemotherapy.

The combination pairs AstraZeneca’s durvalumab with Padcev from Pfizer and Astellas.